A Window for Enhanced Oral Delivery of Therapeutics via Lipid Nanoparticles

References

• Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carr Syst. 2000;17(6):557–620. doi:10.1615/CritRevTherDrugCarrierSyst.v17.i6.10
   PubMed Web of Science ®Google Scholar
• Osti C, Khadka M, Wosti D, Gurung G, Zhao Q. Knowledge and practice towards care and maintenance of peripheral intravenous cannula among nurses in Chitwan Medical College Teaching Hospital, Nepal. Nurs Open. 2019;6:1006–1012. doi:10.1002/nop2.288
   PubMed Web of Science ®Google Scholar
• Fairuz S, Nair RS, Billa N. Orally administered amphotericin B nanoformulations: physical properties of nanoparticle carriers on bioavailability and clinical relevance. Pharmaceutics. 2022;14(9):1823. doi:10.3390/pharmaceutics14091823
   PubMed Web of Science ®Google Scholar
• Sabra R, Billa N. Soliciting the oral route as a logical approach to managing colon cancer. Front Bioeng Biotechnol. 2021;9:645923. doi:10.3389/fbioe.2021.645923
   PubMed Web of Science ®Google Scholar
• Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer’s patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv. 2004;1:141–163. doi:10.1517/17425247.1.1.141
   PubMedGoogle Scholar
• Amekyeh H, Billa N, Yuen KH, Chin SLS. A gastrointestinal transit study on amphotericin B-loaded solid lipid nanoparticles in rats. AAPS Pharm Sci Tech. 2015;16:871–877. doi:10.1208/s12249-014-0279-4
   PubMed Web of Science ®Google Scholar
• Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-The-art. J Control Release. 2016;240:504–526. doi:10.1016/j.jconrel.2016.06.016
   PubMed Web of Science ®Google Scholar
• Lehr CM. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 1994;11:119–160.
   PubMed Web of Science ®Google Scholar
• De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–149. doi:10.2147/IJN.S596
   PubMed Web of Science ®Google Scholar
• Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–227. doi:10.1016/j.riam.2009.06.003
   PubMed Web of Science ®Google Scholar
• Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42(12):821–826. doi:10.1111/j.2042-7158.1990.tb07033.x
   PubMed Web of Science ®Google Scholar
• Du XJ, Wang JL, Iqbal S, et al. The effect of surface charge on oral absorption of polymeric nanoparticles. Biomater Sci. 2018;6(3):642–650. doi:10.1039/C7BM01096F
   PubMed Web of Science ®Google Scholar
• Asad S, Jacobsen A-C, Teleki A. Inorganic nanoparticles for oral drug delivery: opportunities, barriers, and future perspectives. Curr Opin Chem Eng. 2022;38:100869. doi:10.1016/j.coche.2022.100869
   Web of Science ®Google Scholar
• Hu Q, Katti PS, Gu Z. Enzyme-responsive nanomaterials for controlled drug delivery. Nanoscale. 2014;6:12273–12286. doi:10.1039/C4NR04249B
   PubMed Web of Science ®Google Scholar
• Crater JS, Carrier RL. Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci. 2010;10:1473–1483. doi:10.1002/mabi.201000137
   PubMed Web of Science ®Google Scholar
• Zandanel C, Ponchel G, Noiray M, Vauthier C. Nanoparticles facing the gut barrier: retention or mucosal absorption? Mechanisms and dependency to nanoparticle characteristics. Int J Pharm. 2021;609:121147. doi:10.1016/j.ijpharm.2021.121147
   PubMedGoogle Scholar
• Ashford M. Biopharmaceutical principles of drug delivery. Introduction to biopharmaceutics. In: Aulton ME, Taylor KMG, editors. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th. Elsevier Ltd.; 2018.
   Google Scholar
• Homayun B, Lin X, Choi H. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129. doi:10.3390/pharmaceutics11030129
   PubMed Web of Science ®Google Scholar
• Dressman JB, Berardi RR, Dermentzoglou LC, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756–761. doi:10.1023/A:1015827908309
   PubMed Web of Science ®Google Scholar
• Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996;136:117–139. doi:10.1016/0378-5173(96)85200-8
   Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64:557–570. doi:10.1016/j.addr.2011.12.009
   PubMed Web of Science ®Google Scholar
• Gavaghan M. Anatomy and physiology of the esophagus. AORN J. 1999;69(2):370–386. doi:10.1016/S0001-2092(06)62494-0
   Google Scholar
• Zhang L, Russell D, Conway BR, Batchelor H. Strategies and therapeutic opportunities for the delivery of drugs to the esophagus. Crit Rev Ther Drug Carrier Syst. 2008;25:259–304. doi:10.1615/CritRevTherDrugCarrierSyst.v25.i3.20
   PubMed Web of Science ®Google Scholar
• Soybel DI. Anatomy and physiology of the stomach. Surg Clin North Am. 2005;85:875–894. doi:10.1016/j.suc.2005.05.009
   PubMed Web of Science ®Google Scholar
• Koziolek M, Carrière F, Porter CJH. Lipids in the stomach – implications for the evaluation of food effects on oral drug absorption. Pharm Res. 2018;35(3):55. doi:10.1007/s11095-017-2289-x
   PubMed Web of Science ®Google Scholar
• Lemarié F, Cavalier JF, Garcia C, et al. Effect of preduodenal lipase inhibition in suckling rats on dietary octanoic acid (C8:0) gastric absorption and plasma octanoylated ghrelin concentration. Biochim Biophys Acta Mol Cell Biol Lipids. 2016;1861:1111–1120. doi:10.1016/j.bbalip.2016.06.009
   Web of Science ®Google Scholar
• Volk N, Lacy B. Anatomy and physiology of the small bowel. Gastrointest Endosc Clin N Am. 2017;27:1–13. doi:10.1016/j.giec.2016.08.001
   PubMedGoogle Scholar
• Helander HF, Fändriks L. Surface area of the digestive tract-revisited. Scand J Gastroenterol. 2014;49:681–689. doi:10.3109/00365521.2014.898326
   PubMed Web of Science ®Google Scholar
• Kumar D, Phillips SF. The contribution of external ligamentous attachments to function of the ileocecal junction. Dis Colon Rectum. 1987;30:410–416. doi:10.1007/BF02556486
   PubMed Web of Science ®Google Scholar
• Lennernäs H. Human intestinal permeability. J Pharm Sci. 1998;87:403–410. doi:10.1021/js970332a
   PubMed Web of Science ®Google Scholar
• Rubin DC, Langer JC. Anatomy and development-small intestine: anatomy and structural anomalies. In: Podolsky DK, Camilleri M, Shanahan F, Fitz JG, Wang TC, Kalloo AN, editors. Yamada’s Atlas of Gastroenterology. Oxford, UK: Wiley Blackwell; 2016.
   Google Scholar
• Stahl A, Gimeno RE, Tartaglia LA, Lodish HF. Fatty acid transport proteins: a current view of a growing family. Trends Endocrinol Metab. 2001;12:266–273. doi:10.1016/S1043-2760(01)00427-1
   PubMed Web of Science ®Google Scholar
• Cohn SM, Birnbaum EH, Friel CM. Colon: anatomy and structural anomalies. In: Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW, editors. Textbook of Gastroenterology. 5th ed. Hoboken: Wiley-Blackwell; 2009:1369–1385.
   Google Scholar
• Bardal SK, Waechter JE, Martin DS. Applied Pharmacology. St. Louis, MO: Elsevier Health Sciences; 2011.
   Google Scholar
• Jannin V, Lemagnen G, Gueroult P, Larrouture D, Tuleu C. Rectal route in the 21st Century to treat children. Adv Drug Deliv Rev. 2014;73:34–49. doi:10.1016/j.addr.2014.05.012
   PubMed Web of Science ®Google Scholar
• Reinholz J, Landfester K, Mailänder V. The challenges of oral drug delivery via nanocarriers. Drug Deliv. 2018;25:1694–1705. doi:10.1080/10717544.2018.1501119
   PubMed Web of Science ®Google Scholar
• Schenk M, Mueller C. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol. 2008;22:391–409. doi:10.1016/j.bpg.2007.11.002
   PubMed Web of Science ®Google Scholar
• Leal J, Smyth HDC, Ghosh D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int J Pharm. 2017;532:555–572. doi:10.1016/j.ijpharm.2017.09.018
   PubMed Web of Science ®Google Scholar
• Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine. 2010;5:287–306. doi:10.2217/nnm.09.110
   PubMed Web of Science ®Google Scholar
• Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Maturitas. 2012;73:5–18. doi:10.1016/j.maturitas.2012.05.014
   PubMed Web of Science ®Google Scholar
• Lundquist P, Artursson P. Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev. 2016;106:256–276. doi:10.1016/j.addr.2016.07.007
   PubMed Web of Science ®Google Scholar
• Senapati PC, Sahoo SK, Sahu AN. Mixed surfactant based (SNEDDS) self-nanoemulsifying drug delivery system presenting efavirenz for enhancement of oral bioavailability. Biomed Pharmacother. 2016;80:42–51. doi:10.1016/j.biopha.2016.02.039
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420. doi:10.1023/a:1016212804288
   PubMed Web of Science ®Google Scholar
• Ganesan P, Narayanasamy D. Lipid nanoparticles: a challenging approach for oral delivery of BCS Class-II drugs. Futur J Pharm Sci. 2018;4:191–205. doi:10.1016/j.fjps.2018.04.001
   Google Scholar
• U.S. Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry; 2017. Available from: https://www.gmp-compliance.org/files/guidemgr/UCM070246.pdf. Accessed November 15, 2022.
   Google Scholar
• Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23. doi:10.1007/s11095-004-9004-4
   PubMed Web of Science ®Google Scholar
• Camenisch GP. Drug disposition classification systems in discovery and development: a comparative review of the BDDCS, ECCS and ECCCS concepts. Pharm Res. 2016;33:2583–2593. doi:10.1007/s11095-016-2001-6
   PubMed Web of Science ®Google Scholar
• Charalabidis A, Sfouni M, Bergström C, Macheras P. The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS): beyond guidelines. Int J Pharm. 2019;566:264–281. doi:10.1016/j.ijpharm.2019.05.041
   PubMed Web of Science ®Google Scholar
• Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1–10. doi:10.1016/j.ijpharm.2011.08.032
   PubMed Web of Science ®Google Scholar
• Fasano A. Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 1998;16:152–157. doi:10.1016/S0167-7799(97)01170-0
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev. 2001;50:91–101. doi:10.1016/S0169-409X(01)00180-6
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter W. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Elsevier Science; 2009.
   Google Scholar
• Shargel L, Wu-Pong S, Yu AB. Applied Biopharmaceutics & Pharmacokinetics. McGraw-Hill; 2007.
   Google Scholar
• Amidon GE, He X, Hageman MJ. Physicochemical Characterization and Principles of Oral Dosage Form Selection. In: Abraham DJ, editor. Burger’s Medicinal Chemistry and Drug Discovery. Wiley; 2003.
   Google Scholar
• Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64:1020–1037. doi:10.1016/S1734-1140(12)70901-5
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1–2):1–20. doi:10.1016/S0168-3659(00)00339-4
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi:10.1016/j.addr.2013.11.009
   PubMed Web of Science ®Google Scholar
• Gundogdu E, Yurdasiper A. Drug transport mechanism of oral antidiabetic nanomedicines. Int J Endocrinol Metab. 2014;12:1–5. doi:10.1016/j.addr.2013.11.009
   Google Scholar
• Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37–56. doi:10.1016/j.scp.2017.07.002
   Web of Science ®Google Scholar
• Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10:26777–26791. doi:10.1039/D0RA03491F
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177. doi:10.1016/S0939-6411(00)00087-4
   PubMed Web of Science ®Google Scholar
• Wang G, Wang J, Wu W, Tony To SS, Zhao H, Wang J. Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs. Expert Opin Drug Deliv. 2015;12(9):1475–1499. doi:10.1517/17425247.2015.1021681
   PubMed Web of Science ®Google Scholar
• Kovacevic A, Savic S, Vuleta G, Müller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406:163–172. doi:10.1016/j.ijpharm.2010.12.036
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272. doi:10.1016/j.addr.2003.12.002
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242:121–128. doi:10.1016/S0378-5173(02)00180-1
   PubMed Web of Science ®Google Scholar
• Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective. Int J Nanomed. 2007;2:289–300.
   PubMed Web of Science ®Google Scholar
• Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334:157–175. doi:10.1016/j.canlet.2012.07.006
   PubMed Web of Science ®Google Scholar
• Salah E, Abouelfetouh MM, Pan Y, Chen D, Xie S. Solid lipid nanoparticles for enhanced oral absorption: a review. Colloids Surf B. 2020;196:111305. doi:10.1016/j.colsurfb.2020.111305
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Ind Pharm. 2008;34:1394–1405. doi:10.1080/03639040802130061
   PubMed Web of Science ®Google Scholar
• Ménard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol. 2010;3:247–259. doi:10.1038/mi.2010.5
   PubMed Web of Science ®Google Scholar
• Nellans HN. (B) Mechanisms of peptide and protein absorption. (1) Paracellular intestinal transport: modulation of absorption. Adv Drug Deliv Rev. 1991;7:339–364. doi:10.1016/0169-409X(91)90013-3
   Web of Science ®Google Scholar
• Yeh TH, Hsu LW, Tseng MT, et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 2011;32:6164–6173. doi:10.1016/j.biomaterials.2011.03.056
   PubMed Web of Science ®Google Scholar
• Shi LL, Xie H, Lu J, et al. Positively charged surface-modified solid lipid nanoparticles promote the intestinal transport of docetaxel through multifunctional mechanisms in rats. Mol Pharm. 2016;13:2667–2676. doi:10.1021/acs.molpharmaceut.6b00226
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat. 1996;189(Pt 3):1.
   PubMedGoogle Scholar
• Chai GH, Xu Y, Chen SQ, et al. transport mechanisms of solid lipid nanoparticles across Caco-2 cell monolayers and their related cytotoxicology. ACS Appl Mater Interfaces. 2016;8:5929–5940. doi:10.1021/acsami.6b00821
   PubMed Web of Science ®Google Scholar
• Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010;21:53–70. doi:10.3851/IMP1684
   PubMedGoogle Scholar
• Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702–716. doi:10.1016/j.addr.2007.09.007
   PubMed Web of Science ®Google Scholar
• Krishnan Y, Mukundan S, Akhil S, Gupta S, Viswanad V. Enhanced lymphatic uptake of leflunomide loaded nanolipid carrier via chylomicron formation for the treatment of rheumatoid arthritis. Adv Pharm Bull. 2018;8:257–265. doi:10.15171/apb.2018.030
   PubMedGoogle Scholar
• Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42:11–18. doi:10.1016/j.ejps.2010.10.002
   PubMed Web of Science ®Google Scholar
• Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci. 2003;92:1085–1094. doi:10.1002/jps.10368
   PubMed Web of Science ®Google Scholar
• Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Deliv Transl Res. 2020;10:1476–1494. doi:10.1007/s13346-020-00803-7
   PubMed Web of Science ®Google Scholar
• Cho HJ, Park JW, Yoon IS, Kim DD. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: enhanced intestinal absorption and lymphatic uptake. Int J Nanomed. 2014;9:495–504. doi:10.2147/IJN.S56648
   PubMed Web of Science ®Google Scholar
• Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495:439–446. doi:10.1016/j.ijpharm.2015.09.014
   PubMed Web of Science ®Google Scholar
• Baek JS, So JW, Shin SC, Cho CW. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Int J Mol Med. 2012;30:953–959. doi:10.3892/ijmm.2012.1086
   PubMed Web of Science ®Google Scholar
• Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132–140. doi:10.1016/j.ejpb.2017.04.013
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS Pharm Sci Tech. 2019;20(3):121. doi:10.1208/s12249-019-1337-8
   PubMed Web of Science ®Google Scholar
• Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133:238–244. doi:10.1016/j.jconrel.2008.10.002
   PubMed Web of Science ®Google Scholar
• Yuen KH. The transit of dosage forms through the small intestine. Int J Pharm. 2010;395:9–16. doi:10.1016/j.ijpharm.2010.04.045
   PubMed Web of Science ®Google Scholar
• Li Y, Li M, Rantanen J, Yang M, Bohr A. Transformation of nanoparticles into compacts: a study on PLGA and celecoxib nanoparticles. Int J Pharm. 2022;611:121278. doi:10.1016/j.ijpharm.2021.121278
   PubMedGoogle Scholar
• Amekyeh H, Billa N, Yuen KH, Lim SCS. Effect of food status on the gastrointestinal transit of amphotericin B-containing solid lipid nanoparticles in rats. AAPS Pharm Sci Tech. 2016;17:1060–1066. doi:10.1208/s12249-015-0438-2
   PubMed Web of Science ®Google Scholar
• Channer S, Virjee P. The effect of size and shape of tablets on their esophageal transit. J Clin Pharmacol. 1986;26(2):141–146. doi:10.1002/j.1552-4604.1986.tb02922.x
   PubMed Web of Science ®Google Scholar
• Osmanoglou E, Van Der Voort IR, Fach K, et al. Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. Neurogastroenterol Motil. 2004;16:547–556. doi:10.1111/j.1365-2982.2004.00541.x
   PubMed Web of Science ®Google Scholar
• Perkins AC, Wilson CG, Frier M, et al. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. Int J Pharm. 2001;222:295–303. doi:10.1016/S0378-5173(01)00722-0
   PubMedGoogle Scholar
• Okabe H, Suzuki E, Sugiura Y, et al. Development of an easily swallowed film formulation. Int J Pharm. 2008;355:62–66. doi:10.1016/j.ijpharm.2007.11.038
   PubMed Web of Science ®Google Scholar
• Miranda J, Corá L, Américo M, Romeiro F. AC biosusceptometry technique to evaluate the gastrointestinal transit of pellets under influence of prandial state. J Pharm Sci. 2010;99:317–324. doi:10.1002/jps.21794
   PubMed Web of Science ®Google Scholar
• Goodman K, Hodges LA, Band J, Stevens HNE, Weitschies W, Wilson CG. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy. Eur J Pharm Biopharm. 2010;74:84–92. doi:10.1016/j.ejpb.2009.01.004
   PubMed Web of Science ®Google Scholar
• Wilding IR, Hardy JG, Maccari M, Ravelli V, Davis SS. Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazem. Int J Pharm. 1991;76:133–143. doi:10.1016/0378-5173(91)90351-N
   Web of Science ®Google Scholar
• Bateman DN, Whittingham TA. Measurement of gastric emptying by real-time ultrasound. Gut. 1982;23:524–527. doi:10.1136/gut.23.6.524
   PubMed Web of Science ®Google Scholar
• Choe SY, Neudeck BL, Welage LS, Amidon GE, Barnett JL, Amidon GL. Novel method to assess gastric emptying in humans: the pellet gastric emptying test. Eur J Pharm Sci. 2001;14:347–353. doi:10.1016/S0928-0987(01)00196-8
   PubMed Web of Science ®Google Scholar
• Beckers EJ, Jeukendrup AE, Brouns F, Wagenmakers AJM, Saris WHM. Gastric emptying of carbohydrate - medium chain triglyceride suspensions at rest. Int J Sports Med. 1992;13(08):581–584. doi:10.1055/s-2007-1024569
   PubMedGoogle Scholar
• Billa N, Yuen KH, Khader MAA, Omar A. Gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. Int J Pharm. 2000;201(1):109–120. doi:10.1016/S0378-5173(00)00399-9
   PubMedGoogle Scholar
• Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8(3):360–364. doi:10.1023/A:1015849700421
   PubMed Web of Science ®Google Scholar
• Yuen KH, Deshmukh AA, Newton JM, Short M, Melchor R. Gastrointestinal transit and absorption of theophylline from a multiparticulate controlled release formulation. Int J Pharm. 1993;97(1–3):61–77. doi:10.1016/0378-5173(93)90127-2
   Google Scholar
• Weitschies W, Wedemeyer RS, Kosch O, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release. 2005;108(2–3):375–385. doi:10.1016/j.jconrel.2005.08.018
   PubMed Web of Science ®Google Scholar
• Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035–1041. doi:10.1136/gut.29.8.1035
   PubMed Web of Science ®Google Scholar
• Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-Profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–614. doi:10.1111/j.1365-2036.1989.tb00254.x
   PubMed Web of Science ®Google Scholar
• Read NW, Cammack J, Edwards C, Holgate AM, Cann PA, Brown C. Is the transit time of a meal through the small intestine related to the rate at which it leaves the stomach? Gut. 1982;23(10):824–828. doi:10.1136/gut.23.10.824
   PubMed Web of Science ®Google Scholar
• Peh KK, Yuen KH. Indirect gastrointestinal transit monitoring and absorption of theophylline. Int J Pharm. 1996;139(1–2):95–103. doi:10.1016/0378-5173(96)04602-9
   Google Scholar
• Schulze JDR, Waddington WA, Ell PJ, Parsons GE, Coffin MD, Basit AW. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm Res. 2003;20(12):1984–1988. doi:10.1023/B:PHAM.0000008046.64409.bd
   PubMed Web of Science ®Google Scholar
• Dobson CL, Davis SS, Chauhan S, Sparrow RA, Wilding IR. The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations. Pharm Res. 1999;16(1):92–96. doi:10.1023/a:1018827030210
   PubMed Web of Science ®Google Scholar
• Wilson CG. The transit of dosage forms through the colon. Int J Pharm. 2010;395(1–2):17–25. doi:10.1016/j.ijpharm.2010.04.044
   PubMedGoogle Scholar
• Basile M, Neri M, Carriero A, et al. Measurement of segmental transit through the gut in man. A novel approach by the biomagnetic method. Dig Dis Sci. 1992;37(10):1537–1543. doi:10.1007/BF01296499
   PubMed Web of Science ®Google Scholar
• Subramanian DA, Langer R, Traverso G. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. J Nanobiotechnology. 2022;20(1):1–23. doi:10.1186/s12951-022-01539-x
   PubMed Web of Science ®Google Scholar
• Zhang C, Ma Y, Zhang J, et al. modification of lipid-based nanoparticles: an efficient delivery system for nucleic acid-based immunotherapy. Molecules. 2022;27:1–29. doi:10.3390/molecules27061943
   Web of Science ®Google Scholar
• Yuan H, Chen CY, Chai GH, Du YZ, Hu FQ. Improved transport and absorption through gastrointestinal tract by pegylated solid lipid nanoparticles. Mol Pharm. 2013;10(5):1865–1873. doi:10.1021/mp300649z
   PubMed Web of Science ®Google Scholar
• Tan SLJ, Billa N. Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. Pharmaceutics. 2021;13(11):1817. doi:10.3390/pharmaceutics13111817
   PubMed Web of Science ®Google Scholar
• Thedrattanawong C, Manaspon C, Nasongkla N. Controlling the burst release of doxorubicin from polymeric depots via adjusting hydrophobic/hydrophilic properties. J Drug Deliv Sci Technol. 2018;46:446–451. doi:10.1016/j.jddst.2018.06.001
   Web of Science ®Google Scholar
• Mansuri S, Kesharwani P, Jain K, Tekade RK, Jain NK. Mucoadhesion: a promising approach in drug delivery system. React Funct Polym. 2016;100:151–172. doi:10.1016/j.reactfunctpolym.2016.01.011
   Web of Science ®Google Scholar
• Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75–85. doi:10.1016/j.addr.2008.09.008
   PubMed Web of Science ®Google Scholar
• Boegh M, Nielsen HM. Mucus as a barrier to drug delivery - understanding and mimicking the barrier properties. Basic Clin Pharmacol Toxicol. 2015;116(3):179–186. doi:10.1111/bcpt.12342
   PubMed Web of Science ®Google Scholar
• Li R, Deng L, Cai Z, et al. Liposomes coated with thiolated chitosan as drug carriers of curcumin. Mater Sci Eng C. 2017;80:156–164. doi:10.1016/j.msec.2017.05.136
   PubMed Web of Science ®Google Scholar
• Martins ALL, de Oliveira AC, Do Nascimento CMOL, et al. Mucoadhesive properties of thiolated pectin-based pellets prepared by extrusion-spheronization technique. J Pharm Sci. 2017;106:1363–1370. doi:10.1016/j.xphs.2017.01.028
   PubMed Web of Science ®Google Scholar
• Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners? Gut. 2020;69:2232–2243. doi:10.1136/gutjnl-2020-322260
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61:158–171. doi:10.1016/j.addr.2008.11.002
   PubMed Web of Science ®Google Scholar
• Lehr CM, Poelma FGJ, Junginger HE, Tukker JJ. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm. 1991;70:235–240. doi:10.1016/0378-5173(91)90287-X
   Web of Science ®Google Scholar
• Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009;71:505–518. doi:10.1016/j.ejpb.2008.09.028
   PubMed Web of Science ®Google Scholar
• Chowdary KPR, Srinivas L. Mucoadhesive drug delivery systems: a review of current status. Indian Drugs. 2000;37:400–406.
   Google Scholar
• Sankar R, Jain SK. Development and characterization of gastroretentive sustained-release formulation by combination of swelling and mucoadhesive approach: a mechanistic study. Drug Des Devel Ther. 2013;7:1455–1469. doi:10.2147/DDDT.S52890
   PubMed Web of Science ®Google Scholar
• Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57:1556–1568. doi:10.1016/j.addr.2005.07.001
   PubMed Web of Science ®Google Scholar
• George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - A review. J Control Release. 2006;114:1–14. doi:10.1016/j.jconrel.2006.04.017
   PubMed Web of Science ®Google Scholar
• Ch’Ng HS, Park H, Kelly P, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery II: synthesis and evaluation of some swelling, water‐insoluble bioadhesive polymers. J Pharm Sci. 1985;74:399–405. doi:10.1002/jps.2600740407
   PubMed Web of Science ®Google Scholar
• Albrecht K, Bernkop-Schnürch A. Thiomers: forms, functions and applications to nanomedicine. Nanomedicine. 2007;2:41–50. doi:10.2217/17435889.2.1.41
   PubMed Web of Science ®Google Scholar
• Gradauer K, Dünnhaupt S, Vonach C, et al. Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J Control Release. 2013;165:207–215. doi:10.1016/j.jconrel.2012.12.001
   PubMed Web of Science ®Google Scholar
• Lehr C, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm. 1992;78:43–48. doi:10.1016/0378-5173(92)90353-4
   Web of Science ®Google Scholar
• Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015;32:389–402. doi:10.1007/s11095-014-1469-1
   PubMed Web of Science ®Google Scholar
• Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B. 2012;95:1–9. doi:10.1016/j.colsurfb.2012.01.001
   PubMed Web of Science ®Google Scholar
• Chanburee S, Tiyaboonchai W. Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin. Drug Dev Ind Pharm. 2017;43:432–440. doi:10.1080/03639045.2016.1257020
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4:1–16. doi:10.1002/btm2.10143
   Web of Science ®Google Scholar
• Wang JP, Chen YZ, Ge XW, Yu HQ. Gamma radiation-induced grafting of a cationic monomer onto chitosan as a flocculant. Chemosphere. 2007;66:1752–1757. doi:10.1016/j.chemosphere.2006.06.072
   PubMed Web of Science ®Google Scholar
• Deacon MP, McGurk S, Roberts CJ, et al. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J. 2000;563:557–563. doi:10.1042/bj3480557
   Google Scholar
• He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166:75–88. doi:10.1016/S0378-5173(98)00027-1
   Web of Science ®Google Scholar
• Tan JSL, Roberts CJ, Billa N. Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B. Pharm Dev Technol. 2019;24:504–512. doi:10.1080/10837450.2018.1515225
   PubMed Web of Science ®Google Scholar
• Bonferoni MC, Sandri G, Ferrari F, et al. Comparison of different in vitro and ex vivo methods to evaluate mucoadhesion of glycol-palmitoyl chitosan micelles. J Drug Deliv Sci Technol. 2010;20:419–424. doi:10.1016/S1773-2247(10)50073-X
   Web of Science ®Google Scholar
• Ling JTS, Roberts CJ, Billa N. Antifungal and mucoadhesive properties of an orally administered chitosan-coated amphotericin B nanostructured lipid carrier (NLC). AAPS Pharm Sci Tech. 2019;20:1–11. doi:10.1208/s12249-019-1346-7
   Web of Science ®Google Scholar
• Elkomy MH, Elmowafy M, Shalaby K, et al. Development and machine-learning optimization of mucoadhesive nanostructured lipid carriers loaded with fluconazole for treatment of oral candidiasis. Drug Dev Ind Pharm. 2021;47:246–258. doi:10.1080/03639045.2020.1871005
   PubMed Web of Science ®Google Scholar
• Fonte P, Nogueira T, Gehm C, Ferreira D, Sarmento B. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv Transl Res. 2011;1:299–308. doi:10.1007/s13346-011-0023-5
   PubMed Web of Science ®Google Scholar
• Luo Y, Teng Z, Li Y, Wang Q. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polym. 2015;122:221–229. doi:10.1016/j.carbpol.2014.12.084
   PubMed Web of Science ®Google Scholar
• Piazzini V, Cinci L, D’Ambrosio M, Luceri C, Bilia AR, Bergonzi MC. Solid lipid nanoparticles and chitosan-coated solid lipid nanoparticles as promising tool for silybin delivery: formulation, characterization, and in vitro evaluation. Curr Drug Deliv. 2018;16:142–152. doi:10.2174/1567201815666181008153602
   Web of Science ®Google Scholar
• Asfour M, Salama A, Mohsen A. Fabrication of all-trans retinoic acid loaded chitosan/tripolyphosphate lipid hybrid nanoparticles as a novel oral delivery approach for management of diabetic nephropathy in rats. J Pharm Sci. 2021;110:3208–3220. doi:10.1016/j.xphs.2021.05.007
   PubMed Web of Science ®Google Scholar
• Parvez S, Yadagiri G, Karole A, et al. Recuperating biopharmaceutical aspects of amphotericin b and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-leishmanial activity. Front Cell Infect Microbiol. 2020;10:1–12. doi:10.3389/fcimb.2020.570573
   PubMed Web of Science ®Google Scholar
• Wibel R, Braun DE, Hämmerle L, et al. In vitro investigation of thiolated chitosan derivatives as mucoadhesive coating materials for solid lipid nanoparticles. Biomacromolecules. 2021;22:3980–3991. doi:10.1021/acs.biomac.1c00776
   PubMed Web of Science ®Google Scholar
• Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57:1595–1639. doi:10.1016/j.addr.2005.07.005
   PubMed Web of Science ®Google Scholar
• Huckaby JT, Lai SK. PEGylation for enhancing nanoparticle diffusion in mucus. Adv Drug Deliv Rev. 2018;124:125–139. doi:10.1016/j.addr.2017.08.010
   PubMed Web of Science ®Google Scholar
• Fang G, Tang B, Chao Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm. 2015;12:2384–2395. doi:10.1021/acs.molpharmaceut.5b00081
   PubMed Web of Science ®Google Scholar
• Suchaoin W, Pereira De Sousa I, Netsomboon K, et al. Mucoadhesive polymers: synthesis and in vitro characterization of thiolated poly(vinyl alcohol). Int J Pharm. 2016;503:141–149. doi:10.1016/j.ijpharm.2016.03.006
   PubMed Web of Science ®Google Scholar
• Muppalaneni S, Mastropietro D, Omidian H. Mucoadhesive drug delivery systems. In: Bader RA, Putnam DA, editors. Engineering Polymer Systems for Improved Drug Delivery. Wiley; 2013:319–342.
   Google Scholar
• Chickering DE, Mathiowitz E. Bioadhesive microspheres: I. A novel electrobalance-based method to study adhesive interactions between individual microspheres and intestinal mucosa. J Control Release. 1995;34:251–262. doi:10.1016/0168-3659(95)00011-V
   Web of Science ®Google Scholar
• Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Souto EB. Experimental factorial design applied to mucoadhesive lipid nanoparticles via multiple emulsion process. Colloids Surf B Biointerfaces. 2012;100:84–89. doi:10.1016/j.colsurfb.2012.04.014
   PubMed Web of Science ®Google Scholar
• Strugala V, Allen A, Dettmar PW, Pearson JP. Colonic mucin: methods of measuring mucus thickness. Proc Nutr Soc. 2003;62:237–243. doi:10.1079/PNS2002205
   PubMed Web of Science ®Google Scholar
• Netsomboon K, Bernkop-Schnürch A. Mucoadhesive vs. mucopenetrating particulate drug delivery. Eur J Pharm Biopharm. 2016;98:76–89. doi:10.1016/j.ejpb.2015.11.003
   PubMed Web of Science ®Google Scholar
• Boegh M, García-Díaz M, Müllertz A, Nielsen HM. Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation. Eur J Pharm Biopharm. 2015;95:136–143. doi:10.1016/j.ejpb.2015.01.014
   PubMed Web of Science ®Google Scholar
• Lieleg O, Ribbeck K. Biological hydrogels as selective diffusion barriers. Trends Cell Biol. 2011;21:543–551. doi:10.1016/j.tcb.2011.06.002
   PubMed Web of Science ®Google Scholar
• Florek J, Caillard R, Kleitz F. Evaluation of mesoporous silica nanoparticles for oral drug delivery-current status and perspective of MSNs drug carriers. Nanoscale. 2017;9:15252–15277. doi:10.1039/C7NR05762H
   PubMed Web of Science ®Google Scholar
• Lai SK, O’Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104:1482–1487. doi:10.1073/pnas.0608611104
   PubMed Web of Science ®Google Scholar
• Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine. 2011;6:365–375. doi:10.2217/nnm.10.123
   PubMed Web of Science ®Google Scholar
• Taipaleenmäki E, Städler B. Recent advancements in using polymers for intestinal mucoadhesion and mucopenetration. Macromol Biosci. 2020;20(3):1900342. doi:10.1002/mabi.201900342
   Web of Science ®Google Scholar
• Rohrer J, Partenhauser A, Hauptstein S, et al. Mucus permeating thiolated self-emulsifying drug delivery systems. Eur J Pharm Biopharm. 2016;98:90–97. doi:10.1016/j.ejpb.2015.11.004
   PubMed Web of Science ®Google Scholar
• Yu Z, Fan W, Wang L, Qi J, Lu Y, Wu W. Effect of surface charges on oral absorption of intact solid lipid nanoparticles. Mol Pharm. 2019;5013–5024. doi:10.1021/acs.molpharmaceut.9b00861
   PubMedGoogle Scholar
• Menzel C, Bernkop-Schnürch A. Enzyme decorated drug carriers: targeted swords to cleave and overcome the mucus barrier. Adv Drug Deliv Rev. 2018;124:164–174. doi:10.1016/j.addr.2017.10.004
   PubMed Web of Science ®Google Scholar
• Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical Mucus. Mol Pharm. 2009;6:173–181. doi:10.1021/mp8001254
   PubMed Web of Science ®Google Scholar
• Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier. Angew Chem Int Ed Engl. 2008;47:9726–9729. doi:10.1002/anie.200803526
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV. Beyond PEGylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials. Adv Drug Deliv Rev. 2018;124:140–149. doi:10.1016/j.addr.2017.07.015
   PubMed Web of Science ®Google Scholar